Trial Profile
Efficacy of ledipasvir/sofosbuvir and the newest approved sofosbuvir/velpatasvir for treatment naive, cirrhotic, and non-cirrhotic genotype 6 patients with chronic hepatitis C infection
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Dec 2018
Price :
$35
*
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary) ; Sofosbuvir/velpatasvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 22 Nov 2018 Results published in the Alimentary Pharmacology and Therapeutics
- 19 Jul 2018 New trial record
- 05 Jun 2018 Results presented at the Digestive Disease Week 2018